NewsApp (Free)

Read news as it happens
Download NewsApp

Available on  

Rediff News  All News  » Business » Markets end 4-day winning streak, pharma weighs

Markets end 4-day winning streak, pharma weighs

Last updated on: May 20, 2013 17:50 IST

BSE graphMarkets ended marginally lower on Monday, snapping four day winning streak, weighed down by pharma shares on worries that the new price control will sharply reduce drug prices thereby impacting growth and profitability.

The 30-share Sensex ended at 20,224 down 62 points or 0.31% and the 50-share Nifty ended at 6,157down by 30 points or 0.49%.

On the international front, rising optimism about global growth pushed world shares to a near five-year high on Monday, while comments from Japan's economy minister that consumers could suffer if the yen falls further lifted it off a 4-1/2 year low.

Data last week that showed US consumer sentiment at its strongest in nearly six years continued to support equity markets. MSCI's world index is at its highest since June 2008 as top European shares started the week up 0.2%.

The Nikkei share average surged to a fresh 5-1/2 year high on Monday, buoyed by further weakness in the yen and optimism over the growth outlook after the Japanese government raised its assessment of the economy for the first time in two months.

Signs of an improving US economy and Wall Street's record closing high on Friday cemented the positive mood in markets.

The Nikkei climbed 1.5% to 15,360.81, the highest closing mark since December 2007.

During the day, the index rose as high as 15,381.74, the highest level for the same period.

Meanwhile, Gold prices today fell by Rs 399, or 1.54%, to Rs 25,556 per 10 grams in futures trade in line with weak overseas trends.

Analysts said sustained weakness in the overseas markets, where gold dipped to one-month low, put pressure on the precious metal prices at futures trade.

On the sectoral front, BSE Healthcare index slumped by nearly 2% followed by counters like Consumer Durable, Banks, Oil & Gas and PSU shares, all falling down by 1% each.

However, BSE Auto and IT indices gained by nearly 1% each.

Shares of pharmaceutical companies were under pressure, declining up to 6% on Bombay Stock Exchange.

Ranbaxy Laboratories, Lupin, GlaxoSmithkline Consumer Healthcare, Venus Remedies and Elder Pharma were down in the range of 5-6%

after the government notification on the new Drug Price Control Order.

The new order will bring 652 drugs under price control and will enable the National Pharmaceutical Pricing Policy 2012 to regulate prices of 348 drugs covered under the National List of Essential Medicines 2011.

The new price control is likely to reduce prices of many drugs in the domestic market and will definitely impact the growth and profitability of the companies in the immediate term, analysts say.

Financial shares like ICICI Bank, HDFC, HDF Bank and SBI fell between 0.5-2% on account of profit booking.

Bharti Airtel was the top Sensex loser, down over 2%. Other notable losers were ONGC, JSPL, NTPC, RIL and Tata Power.

Lupin ended lower by over 4% on BSE after rival Mylan Inc's on Friday launched a generic version of the cholesterol-lowering Tricor in the US.

GraphOn the gaining side, auto stocks were in demand with M&M, Maruti Suzuki, Hero Moto Bajaj Auto and Tata Motors spurting between 1-2% as reports suggest encouraging sales growth during the current month.

Infosys gained over 1%. The company said on Monday it would challenge a Rs 576.9 crores income tax demand raised by Indian authorities earlier this month.

Coal India ended higher ahead of it’s a standalone Q4 (January-March) earnings later in the day.

The market breadth in BSE ended weak with 1,302 shares declining and 1,116 shares advancing.


Voltamp Transformers rallied 20% after announcing a total dividend of 150% or Rs 15 per share which includes a special dividend.

GlaxoSmithkline Consumer Healthcare tanked 6% to Rs 4,729 on profit taking after surging 26% in past one week on the Bombay Stock Exchange.

Apollo Hospitals Enterprise dipped 7% on reporting a 27% year-on-year (yoy) jump in standalone net profit at Rs 75.52 crore for the quarter ended March 31, 2013 (Q4) on the back of one-time gain due to sale of assets.

Surabhi Roy in Mumbai